Cover Image
市場調查報告書

子宮肌瘤(Uterine leiomyoma) - 開發平台分析

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 234336
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
子宮肌瘤(Uterine leiomyoma) - 開發平台分析 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 95 Pages
簡介

子宮肌瘤是發生在子宮的良性腫瘤。雖然肌瘤和子宮壁(子宮平滑肌)一樣是平滑纖維,但卻較正常子宮肌層更厚,一般呈球型腫塊。子宮肌瘤最常見的症狀有嚴重的月經出血,月經持續七天以上,骨盤壓或疼痛、頻尿、排尿障礙、便秘及背部疼痛和下肢痛等。

本報告提供子宮肌瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等,以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

子宮肌瘤概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Euroscreen S.A.
  • Takeda Pharmaceutical Company Limited
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Kissei Pharmaceutical Co., Ltd.
  • Bayer AG
  • BioSpecifics Technologies Corp.
  • Repros Therapeutics Inc.
  • Dongkook Pharmaceutical Co., Ltd.
  • HRA Pharma
  • AbbVie Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ulipristal acetate
  • relugolix
  • elagolix sodium
  • telapristone acetate
  • mifepristone
  • KLH-2109
  • vilaprisan
  • ESN-364
  • LFA-102
  • collagenase clostridium histolyticum
  • GnRH Antagonists
  • EVE-104
  • triptorelin pamoate biosimilar
  • Drug to Activate Progesterone Receptor for Uterine Fibroids
  • Drugs for Women Health

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8278IDB

Summary

Global Markets Direct's, 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2016', provides an overview of the Uterine Leiomyoma (Uterine Fibroids) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
  • The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects
  • The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uterine Leiomyoma (Uterine Fibroids) Overview
  • Therapeutics Development
    • Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview
    • Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies
  • Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes
  • Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Addex Therapeutics Ltd
    • Bayer AG
    • BioSpecifics Technologies Corp.
    • Dongkook Pharmaceutical Co., Ltd.
    • Euroscreen S.A.
    • Kissei Pharmaceutical Co., Ltd.
    • Laboratoire HRA Pharma
    • Repros Therapeutics Inc.
    • Takeda Pharmaceutical Company Limited
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • collagenase clostridium histolyticum - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elagolix sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVE-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KLH-2109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relugolix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telapristone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulipristal acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vilaprisan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPEA-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
  • Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
      • May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
      • May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
      • Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
      • Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
      • Dec 21, 2015: Repros Updates Proellex Program
      • Nov 12, 2015: Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex in Women With Symptomatic Uterine Fibroid Bleeding
      • Oct 09, 2015: Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids
      • Sep 16, 2015: Abbvie Announces Plans To Proceed To Phase 3 Evaluation Of Elagolix In Patients With Uterine Fibroids
      • May 28, 2015: European Commission approves Esmya 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
      • Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
      • Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
      • Dec 29, 2014: Repros Initiates Two Phase 2B Uterine Fibroid Studies
      • Oct 16, 2014: BioSpecifics Technologies Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine
      • Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2016
  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2016
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2016
  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top